삼성바이오로직스

207940KOSPI

62.5 / 100

Reference Date: 2026-10-23

Financial Score24.0 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 3.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung BioLogics is a global CDMO (Contract Development and Manufacturing Organization) providing biopharmaceutical contract manufacturing and development services. In 2025, it restructured into a pure-play CDMO business by spinning off Samsung Epics Holdings. The company generates significant revenue from Europe and the U.S. and is expanding into next-generation biopharmaceuticals such as mRNA, ADC, and cell/gene therapies.

Number of Employees

10,910people

Average Salary

114.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

35.31Industry Average 15.000.0Point

2.4x industry avg (risky)

PBR

8.46Industry Average 1.200.0Point

7.1x industry avg (risky)

ROE

19.44Industry Average 8.007.0Point

2.4x industry avg (excellent)

Debt Ratio

14.45Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲37.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 13.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 1,361,000Won52-week high 1,965,00052-week low 1,179,000

1-month return2.0Point

1m -3.13% (slight drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

13 totalPositive 3Neutral 10Negative 0

Neutral[기재정정]증권신고서(지분증권)2026-10-22
Neutral[기재정정]투자설명서2026-10-22
Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-10-21
Neutral[기재정정]연결재무제표기준영업실적등에대한전망(공정공시)2026-10-21
Neutral[기재정정]주요사항보고서(타법인주식및출자증권양수결정)2026-10-16